中恒集团专利数量超340件

Core Insights - The company emphasizes technological innovation as a core engine for growth, focusing on research system reform and major project breakthroughs to create a comprehensive innovation ecosystem [1] Group 1: Innovation and Development - The company has developed a Class 1 innovative traditional Chinese medicine, "Sanqi Granules," which received clinical trial approval from the National Medical Products Administration in April 2023, aiming to enter Phase II and III studies for chronic glomerulonephritis patients [1] - The subsidiary, Laimei Pharmaceutical, achieved significant results, ranking in the top 50 of the "2024 China Innovative Drug Value Ranking Comprehensive Strength List" [1] - The global first nano carbon iron project undertaken by the subsidiary Sichuan Yingrui Pharmaceutical is progressing steadily, with the nano carbon suspension injection entering the international stage and being selected as one of Chongqing's first batch of iconic future industry products [1] Group 2: Collaboration and Research - The company focuses on deep integration of production, education, and research, promoting the development of ASEAN characteristic medicinal materials and traditional Chinese medicine innovation [1] - A joint application with Shanghai University of Traditional Chinese Medicine for the "Modernization of Traditional Chinese Medicine" national key research and development plan has been successfully approved, aiding in the establishment of a quality control standard system for traditional Chinese medicine [1] Group 3: Achievements and Recognition - The company has been approved for 7 national and provincial-level research projects, receiving nearly 3 million yuan in financial subsidies [1] - The project "Research and Development Application Demonstration of the 'Nature-Effect-Material' Theory of Traditional Chinese Medicine and Ethnic Medicine," in collaboration with universities, won the second prize of the 2024 Guangxi Science and Technology Progress Award [1] - The company has established 22 provincial and ministerial-level research platforms, holds over 340 effective patents, with nearly 70% being invention patents, and has received 7 China Patent Awards for excellence and 8 Guangxi Invention Creation Exhibition Awards, reinforcing its technological barriers [1]